Physician profile
Jay Schwartz
NPI 1730134867
$30,073.31
in general payments reported to CMS, 2019-2025
21 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $3,049 · 2021: $670 · 2022: $571 · 2023: $506 · 2024: $23K · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $2,749 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,000.00 |
| Food and Beverage | $2,749.33 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $22,545.72 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $2,879.16 | 2019-2025 | Amo Phaco Needle |
| Alcon Vision LLC | $1,582.10 | 2019-2025 | Clareon, Clareon Panoptix Pro, Eysuvis |
| Sun Pharmaceutical Industries INC. | $1,319.19 | 2019-2025 | Bromsite, Cequa, Xelpros |
| Allergan, INC. | $451.85 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $332.77 | 2022-2025 | Stellaris, Envista Mx60 Iol, Miebo |
| Tarsus Pharmaceuticals, INC. | $236.64 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $235.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $106.71 | 2019-2021 | |
| Abbvie INC. | $66.35 | 2022-2023 | Vuity, Lumigan |
| Harrow Eye, LLC | $59.04 | 2024 | Vevye, Iheezo, Flarex |
| Kala Pharmaceuticals, INC. | $55.79 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $49.46 | 2021 | |
| Dompe US, INC. | $37.31 | 2024-2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $26.36 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.55 | 2020 | |
| Ocular Therapeutix, INC. | $19.35 | 2025 | Dextenza |
| Shire North American Group INC | $17.88 | 2019 | |
| Staar Surgical Company | $15.19 | 2019 | |
| Ivantis, INC | $13.42 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.